Holick, M F. Vitamin D deficiency. New Engl J Med
2007; 357: 266–81.
Vanlint, S, Nugent, M, Durvasula, S. Vitamin D and people with intellectual disability. Aust Fam Physician
2008; 37: 348–51.
Vanlint, S, Nugent, M. Vitamin D and fractures in people with intellectual disability. J Intellect Dis Res
2006; 50: 761–7.
Zubillaga, P, Garrido, A, Mugica, I, Ansa, J, Zabalza, R, Emparanza, JI. Effect of vitamin D and calcium supplementation on bone turnover in institutionalized adults with Down's Syndrome. Eur J Clin Nutr
2006; 60: 605–9.
Kilpinen-Loisa, P, Arvio, M, Ilvesmäki, V, Mäkitie, O. Vitamin D status and optimal supplementation in institutionalized adults with intellectual disability. J Intellect Disabil Res
2009; 53: 1014–23.
Wong, TS, Lau, VM, Lim, W, Fung, G. A survey of vitamin D level in people with learning disability in long-stay hospital wards in Hong Kong. J Intellect Disabil
2006; 10: 47–59.
Srikanth, R, Cassidy, G, Joiner, C, Teeluckdharry, S. Osteoporosis in people with intellectual disabilities: a review and a brief study of risk factors for osteoporosis in a community sample of people with intellectual disabilities. J Intellect Disabil Res
2011; 55: 53–62
Schrager, S, Kloss, C, Ju, AW
Prevalence of fractures in women with intellectual disabilities: a chart review. J Intellect Disabil Res
2007; 5: 253–9.
Tannenbaum, TN, Lipworth, L, Baker, S. Risk of fractures in an intermediate care facility for persons with mental retardation. Am J Ment Retard
1989; 93: 444–51.
Lohiya, GS, Crinella, FM, Tan-Figueroa, L, Caires, S, Lohiya, S. Fracture epidemiology and control in a developmental center. West J Med
1999; 170: 203–9.
Glick, NR, Fischer, MH, Heisey, DM, Leverson, GE, Mann, DC. Epidemiology of fractures in people with severe and profound developmental disabilities. Osteoporosis Int
2005; 16: 389–96
Jancar, J, Jancar, MP. Age-related fractures in people with intellectual disability and epilepsy. J Intellect Disabil Res
1998; 42: 429–33.
Institute of Medicine. Dietary Reference Intakes for Calcium and Vitamin D.
National Academy Press, 2010.
Frighi, V, Stephenson, MT, Morovat, A, Jolley, IE, Trivella, M, Dudley, CA, et al. Safety of antipsychotics in people with intellectual disability. Br J Psychiatry
2011; 199: 289–95.
Petty, SJ, O'Brien, TJ, Wark, JD. Anti-epileptic medication and bone health. Osteoporosis Int
2007; 18: 129–42.
Webb, AR, Kline, L, Holick, MF. Influence of season and latitude on the cutaneous synthesis of vitamin D3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. J Clin Endocrinol Metab
1988; 67: 373–8.
Hyppönen, E, Power, C. Hypovitaminosis D in British adults at age 45 y: nationwide cohort study of dietary and lifestyle predictors. Am J Clin Nutr
2007; 85: 860–8.
Bouillon, R, Van Schoor, NM, Gielen, E, Boonen, S, Matthieu, C, Vanderschueren, D, et al. Optimal vitamin D status: a critical analysis on the basis of evidence-based medicine. J Clin Endocrinol Metab
2013; 98: E1283–304.
Lawson, DE, Paul, AA, Black, AE, Cole, TJ, Mandal, AR, Davie, M. Relative contributions of diet and sunlight to vitamin D state in the elderly. Br Med J
1979; 2: 303–5.
Black, LJ, Walton, J, Flynn, A, Kiely, M. Adequacy of vitamin D intakes in children and teenagers from the base diet, fortified foods and supplements. Public Health Nutr
2014; 17: 721–31.
Wang, TJ, Zhang, F, Richards, JB, Kestenbaum, B, van Meurs, JB, Berry, D, et al. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet
2010; 376: 180–8
Faurschou, A, Beyer, DM, Schmedes, A, Bogh, MK, Philipsen, PA, Wulf, HC. The relation between sunscreen layer thickness and vitamin D production after ultraviolet B exposure: a randomized clinical trial. Br J Dermatol
2012; 167: 391–5
Hawli, Y, Nasrallah, M, El-Hajj Fuleihan, G. Endocrine and musculoskeletal abnormalities in patients with Down syndrome. Nat Rev Endocrinol
2009; 5: 327–34
Adami, S, Giannini, S, Bianchi, G, Sinigaglia, L, Di Munno, O, Fiore, CE, et al. Vitamin D status and response to treatment in post-menopausal osteoporosis. Osteoporosis Int
2009; 20: 239–44
National Institute for Health and Care Excellence. Alendronate, Etidronate, Risedronate, Raloxifene, Strontium Ranelate and Teriparatide for the Secondary Prevention of Osteoporotic Fragility Fractures in Postmenopausal Women.
NICE, 2008 (http://www.nice.org.uk/nicemedia/live/11748/42508/42508.pdf)
Reid, IR, Bolland, MJ, Grey, A. Effects of vitamin D supplements on bone mineral density: a systematic review and meta-analysis. Lancet
2014; 383: 146–55.
Lawrence, TM, White, CT, Wenn, R, Moran, CG. The current hospital costs of treating hip fractures. Injury
2005; 36: 88–91.
Bischoff-Ferrari, HA, Willett, WC, Orav, EJ, Lips, P, Meunier, PJ, Lyons, RA, et al. A pooled analysis of Vitamin D dose requirements for fracture prevention. N Engl J Med
2012; 367: 40–9.
Itzhaky, D, Amital, D, Gorden, K, Bogomolni, A, Arnson, Y, Amital, H. Low serum vitamin D concentrations in patients with schizophrenia. Isr Med Assoc J
2012; 14: 88–92.
Tiangga, E, Gowda, A, Dent, JA. Vitamin D deficiency in psychiatric in-patients and treatment with daily supplements of calcium and ergocalciferol. Psychiatr Bull
2008; 32: 390–3.
Agorastos, A, Weinas, A, Agorastos, AD, Wiedemann, K. Psychosis-induced vitamin D deficiency with secondary hyperparathyroidism and osteoporotic fractures. Gen Hosp Psychiatry
2011; 33: 641.e3–5.
Gracious, BL, Finucane, TL, Friedman-Campbell, M, Messing, S, Parkhurst, MN. Vitamin D deficiency and psychotic features in mentally ill adolescents: a cross-sectional study. BMC Psychiatry
2012; 12: 38.
Crews, M, Lally, J, Gardner-Sood, P, Howes, O, Bonaccorso, S, Smith, S, et al. Vitamin D deficiency in first episode psychosis: a case-control study. Schizophr Res
2013; 150: 533–7.
Kishimoto, T, De Hert, M, Carlson, HE, Manu, P, Correll, CU. Osteoporosis and fracture risk in people with schizophrenia. Curr Opin Psychiatry
2012; 25: 415–29.
Yoon, V, Maalouf, NM, Sakhaee, K. The effects of smoking on bone metabolism. Osteoporos Int
2012; 23: 2081–92.
Abukhadir, SS, Mohamed, N, Mohamed, N. Pathogenesis of alcohol-induced osteoporosis and its treatment: a review. Curr Drug Targets
2013; 14: 1601–10.
Kishimoto, T, Watanabe, K, Shimada, N, Makita, K, Yagi, G, Kashima, H. Antipsychotic-induced hyperprolactinemia inhibits the hypothalamo-pituitary-gonadal axis and reduces bone mineral density in male patients with schizophrenia. J Clin Psychiatry
2008; 69: 385–91.
Meaney, AM, O'Keane, V. Bone mineral density changes over a year in young females with schizophrenia: relationship to medication and endocrine variables. Schizophrenia Res
2007; 93: 136–43.
De Hert, M, Correll, CU, Bobes, J, Cetkovich-Bakmas, M, Cohen, D, Asai, I, et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry
2011; 10: 138–51.